



ALLIANCE HEALTHCARE GROUP LIMITED

(Incorporated in the Republic of Singapore on 6 June 2006)
(UEN. 200608233K)

Alliance Healthcare Group Limited and its Subsidiaries

Condensed interim financial statements
For the six months and the full year ended 30 June 2023

*This announcement has been reviewed by the Company's sponsor, RHB Bank Berhad, through its Singapore branch (the "**Sponsor**") in accordance with Rule 226(2)(b) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Alvin Soh, Head, Corporate Finance, RHB Bank Berhad, Singapore branch, at 90 Cecil Street, #03-00 Singapore 069531, Telephone: +65 6320 0627*



Table of Contents	Page
A. Condensed interim consolidated statement of profit or loss and other comprehensive income	1
B. Condensed interim statements of financial position	2
C. Condensed interim statements of changes in equity	3
D. Condensed interim consolidated statement of cash flows	5
E. Notes to the condensed interim financial statements	7
F. Other information required by appendix 7C of the Catalist rules	28

Reporting Period

Current Reporting Period: full year ended 30 June 2023 (“**FY2023**”)

Corresponding period of the immediately preceding financial year: full year ended 30 June 2022 (“**FY2022**”)



A. Condensed interim consolidated statement of profit or loss and other comprehensive income

	Note	Group 6 months ended 30 June			Group 12 months ended 30 June		
		2023	2022	Variance %	2023	2022	Variance %
		S\$	S\$		S\$	S\$	
Revenue	4	29,084,636	26,189,221	11.1	58,004,658	54,756,751	5.9
Interest income		5,808	-	n.m.	5,808	-	n.m.
Other income and gains		595,763	968,130	(38.5)	1,144,098	1,761,394	(35.0)
Consumables and medical supplies used		(9,196,158)	(7,369,939)	24.8	(18,261,093)	(15,636,903)	16.8
Employee benefits expense		(16,474,092)	(14,447,922)	14.0	(31,325,468)	(29,416,493)	6.5
Depreciation and amortisation expense		(1,429,753)	(1,377,318)	3.8	(2,805,582)	(2,796,216)	0.3
Other losses		(3,933)	(29,785)	(86.8)	(6,856)	(35,609)	(80.7)
Finance costs		(274,411)	(108,328)	153.3	(420,608)	(227,721)	84.7
Other expenses		(1,850,222)	(1,617,621)	14.4	(4,097,741)	(3,387,822)	21.0
Share of results of an associate		(75,660)	(43,671)	73.2	(82,208)	(66,495)	23.6
Profit before tax	6	381,978	2,162,767	(82.3)	2,155,008	4,950,886	(56.5)
Income tax expense	7	(333,004)	(450,785)	(26.1)	(145,463)	(643,374)	(77.4)
Profit for the financial period, net of tax		48,974	1,711,982	(97.1)	2,009,545	4,307,512	(53.3)
Other comprehensive loss:							
<u>Items that may be reclassified subsequently to profit or loss:</u>							
Exchange differences on translating foreign operations, net of tax		(5,956)	(2,912)	104.5	(10,764)	(3,023)	256.1
Total other comprehensive loss for the period, net of tax		(5,956)	(2,912)	104.5	(10,764)	(3,023)	256.1
Total comprehensive income for the period		43,018	1,709,070	(97.5)	1,998,781	4,304,489	(53.6)
Profit/(loss) attributable to:							
– Owners of the parent		170,497	1,429,174	(88.1)	2,090,833	3,112,254	(32.8)
– Non-controlling interests		(121,523)	282,808	(143.0)	(81,288)	1,195,258	(106.8)
Profit for the financial period, net of tax		48,974	1,711,982	(97.1)	2,009,545	4,307,512	(53.3)
Total comprehensive income/(loss) attributable to:							
– Owners of the parent		164,541	1,426,262	(88.5)	2,080,069	3,109,231	(33.1)
– Non-controlling interests		(121,523)	282,808	(143.0)	(81,288)	1,195,258	(106.8)
Total comprehensive income for the period		43,018	1,709,070	(97.5)	1,998,781	4,304,489	(53.6)

*n.m denotes not meaningful



B. Condensed interim statements of financial position

	Note	Group		Company	
		30-Jun-23 S\$	30-Jun-22 S\$	30-Jun-23 S\$	30-Jun-22 S\$
ASSETS					
Non-current assets					
Property, plant and equipment	12	7,568,610	6,594,276	144,090	130,406
Right-of-use assets		4,183,098	2,532,043	-	18,332
Investment properties	13	-	-	4,690,736	3,820,183
Investment in subsidiaries		-	-	5,877,632	5,877,632
Investment in an associate		481,297	563,505	-	-
Intangible assets	11	5,595,856	5,725,840	-	-
Trade and other receivables		762,473	562,473	200,000	-
Deferred tax assets		47,392	47,392	-	-
Total non-current assets		18,638,726	16,025,529	10,912,458	9,846,553
Current assets					
Inventories		3,201,807	2,424,060	-	4,100
Financial assets - derivatives		88,475	89,962	-	-
Trade and other receivables		22,114,370	11,655,001	15,658,637	11,437,247
Income tax receivables		-	4,350	106,072	-
Other non-financial assets		1,352,705	716,328	106,568	106,551
Cash and cash equivalents		19,551,617	20,714,704	1,370,298	892,500
Total current assets		46,308,974	35,604,405	17,241,575	12,440,398
Total assets		64,947,700	51,629,934	28,154,033	22,286,951
EQUITY AND LIABILITIES					
Equity attributable to owners of the parent					
Share capital	15	14,684,250	14,684,250	14,684,250	14,684,250
Treasury shares	15	(373,360)	(199,400)	(373,360)	(199,400)
Retained earnings		13,616,698	12,451,733	3,666,117	1,687,983
Other reserves		(5,114,060)	(4,717,861)	80,214	-
Equity, attributable to owners of the parent		22,813,528	22,218,722	18,057,221	16,172,833
Non-controlling interests		939,462	1,787,961	-	-
Other reserve		-	(94,578)	-	-
Total equity		23,752,990	23,912,105	18,057,221	16,172,833
Non-current liabilities					
Financial liabilities - lease liabilities		2,402,153	1,143,055	-	-
Loans and borrowings	14	7,260,912	4,433,303	4,904,448	2,367,545
Deferred tax liabilities		68,438	90,535	-	-
Total non-current liabilities		9,731,503	5,666,893	4,904,448	2,367,545
Current liabilities					
Income tax payable		767,829	798,355	-	-
Trade and other payables		26,316,259	17,977,815	3,991,538	3,461,223
Provision		185,000	175,000	-	-
Other non-financial liabilities		66,679	104,239	-	-
Financial liabilities - lease liabilities		1,892,075	1,463,832	-	18,703
Loans and borrowings	14	2,235,365	1,531,695	1,200,826	266,647
Total current liabilities		31,463,207	22,050,936	5,192,364	3,746,573
Total liabilities		41,194,710	27,717,829	10,096,812	6,114,118
Total equity and liabilities		64,947,700	51,629,934	28,154,033	22,286,951



C. Condensed interim statements of changes in equity

Group	Note	Attributable to owners of the parent						Non-controlling interests	Other reserves
		Total equity S\$	Sub-total S\$	Share capital S\$	Treasury shares S\$	Retained earnings S\$	Other reserves S\$		
Opening balance at 1 July 2022		23,912,105	22,218,722	14,684,250	(199,400)	12,451,733	(4,717,861)	1,787,961	(94,578)
Changes in equity:									
Total comprehensive income/(loss) for the year		1,998,781	2,080,069	-	-	2,090,833	(10,764)	(81,288)	-
Share buy back	15	(173,960)	(173,960)	-	(173,960)	-	-	-	-
Performance share plan									
- Value of employee services	6	80,214	80,214	-	-	-	80,214	-	-
Dividends paid	8	(925,868)	(925,868)	-	-	(925,868)	-	-	-
Dividends paid to non-controlling interests in subsidiaries		(440,350)	-	-	-	-	-	(440,350)	-
Acquisition of non-controlling interest without a change in control	16	(780,417)	(465,649)	-	-	-	(465,649)	(326,861)	12,093
Put option expired		82,485	-	-	-	-	-	-	82,485
Closing balance at 30 June 2023		23,752,990	22,813,528	14,684,250	(373,360)	13,616,698	(5,114,060)	939,462	-
Opening balance at 1 July 2021		20,539,659	19,787,034	14,684,250	-	9,817,622	(4,714,838)	1,278,761	(526,136)
Changes in equity:									
Total comprehensive income/(loss) for the year		4,304,489	3,109,231	-	-	3,112,254	(3,023)	1,195,258	-
Share buy back	15	(199,400)	(199,400)	-	(199,400)	-	-	-	-
Dividends paid	8	(478,143)	(478,143)	-	-	(478,143)	-	-	-
Dividends paid to non-controlling interests in subsidiaries		(254,500)	-	-	-	-	-	(254,500)	-
Acquisition of non-controlling interest without a change in control		-	-	-	-	-	-	(431,558)	431,558
Closing balance at 30 June 2022		23,912,105	22,218,722	14,684,250	(199,400)	12,451,733	(4,717,861)	1,787,961	(94,578)



C. Condensed interim statements of changes in equity (cont'd)

Company	Note	Total equity S\$	Share capital S\$	Treasury shares S\$	Retained earnings S\$	Other reserves S\$
Opening balance at 1 July 2022		16,172,833	14,684,250	(199,400)	1,687,983	-
Changes in equity:						
Total comprehensive income for the year		2,904,001	-	-	2,904,001	-
Share buyback	15	(173,960)	-	(173,960)	-	-
Performance share plan						
- Value of employee services	6	80,214	-	-	-	80,214
Dividends paid	8	(925,867)	-	-	(925,867)	-
Closing balance at 30 June 2023		18,057,221	14,684,250	(373,360)	3,666,117	80,214
Opening balance at 1 July 2021		16,088,821	14,684,250	-	1,404,571	-
Changes in equity:						
Total comprehensive income for the year		761,555	-	-	761,555	-
Share buyback	15	(199,400)	-	(199,400)	-	-
Dividends paid	8	(478,143)	-	-	(478,143)	-
Closing balance at 30 June 2022		16,172,833	14,684,250	(199,400)	1,687,983	-



D. Condensed interim consolidated statement of cash flows

	Group	
	12 months ended 30 June	
	2023	2022
Note	S\$	S\$
<u>Cash flows from operating activities</u>		
Profit before tax	2,155,008	4,950,886
Adjustments for:		
Performance share plan expense	80,214	-
Depreciation of property, plant and equipment	790,601	810,949
Depreciation of right-of-use assets	1,884,997	1,843,347
Amortisation of intangible assets	129,984	141,920
Loss on disposal of plant and equipment	521	-
Plant and equipment written off	-	459
Interest expense	307,561	125,981
Lease interest expense	113,047	101,740
Rental rebates	-	(400,547)
Government grant	-	-
Interest income	(5,808)	-
Fair value gain on derivative financial instruments, net	(53,766)	(34,159)
Share of results of an associate	82,208	66,495
Operating cash flows before changes in working capital	5,484,567	7,607,071
<u>Changes in working capital:</u>		
Inventories	(777,747)	(155,909)
Trade and other receivables	(10,459,369)	1,913,569
Other non-financial assets	(97,045)	(109,886)
Trade and other payables	8,560,130	1,051,605
Other non-financial liabilities	(37,560)	(68,305)
Net effect of exchange rate changes in consolidating foreign operations	(9,563)	(2,878)
Net cash flows from operations	2,663,413	10,235,267
Income tax paid	(193,736)	(419,533)
Net cash flows from operating activities	2,469,677	9,815,734
<u>Cash flows from investing activities</u>		
Interest received	5,808	-
Acquisition of non-controlling interest without a change in control	(800,610)	(720,630)
Acquisition of an associate	-	(630,000)
Loan to an associate	(200,000)	(610,000)
Purchase of property, plant and equipment	12 (2,296,110)	(423,110)
Net cash flows used in investing activities	(3,290,912)	(2,383,740)



D. Condensed interim consolidated statement of cash flows (cont'd)

	Group	
	12 months ended 30 June	
	2023	2022
Note	S\$	S\$
Cash flows from financing activities		
Lease liabilities – principal and interest paid	(1,961,639)	(1,540,556)
Movements in amount due to related parties	(125,731)	(288,376)
Increase in borrowings	4,715,543	300,000
Decrease in other financial liabilities	(1,084,078)	(795,897)
Finance lease repayments	(38,208)	(68,208)
Dividends paid to equity holders of the Company	(925,868)	(478,143)
Dividends paid to non-controlling interests	(440,350)	(254,500)
Share buyback	(173,960)	(199,400)
Interest paid	(307,561)	(125,981)
Net cash flows used in financing activities	<u>(341,852)</u>	<u>(3,451,061)</u>
Net (decrease) increase in cash and cash equivalents	(1,163,087)	3,980,933
Cash and cash equivalents, statement of cash flows, beginning balance	20,689,704	16,708,771
Cash and cash equivalents, statement of cash flows, ending balance ⁽¹⁾	<u>19,526,617</u>	<u>20,689,704</u>

Note (1):

For the purpose of presenting the consolidated statement of cash flows, cash and cash equivalents comprise the following:

	Group	
	30 June	
	2023	2022
	S\$	S\$
Cash and bank balances	19,551,617	20,714,704
Less: Bank deposits pledged (a)	(25,000)	(25,000)
Cash and cash equivalents per consolidated statement of cash flows	<u>19,526,617</u>	<u>20,689,704</u>

(a) This is for amounts held by the bankers as security for the Merchant Agreement between the bank and the group.



E. Notes to the condensed interim consolidated financial statements

1. Corporate information

Alliance Healthcare Group Limited (the “**Company**”) is incorporated in Singapore with limited liability. The financial statements are presented in Singapore dollars. These condensed interim consolidated financial statements as at and for the six months and twelve months ended 30 June 2023 comprise the Company (referred to as “**parent**”) and its subsidiaries (collectively, the “**Group**”).

The principal activities of the Group are:

- a) investment holding company and provision of administrative and management services;
- b) the provision of managed healthcare solutions;
- c) the wholesale of pharmaceutical products;
- d) the provision of medical services; and
- e) the provision of mobile and digital health services.

2. Basis of preparation

The condensed interim financial statements for the six months and twelve months ended 30 June 2023 have been prepared in accordance with the Singapore Financial Reporting Standards (International) SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last annual financial statements for the year ended 30 June 2022.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollar which is the Company’s functional currency.

2.1 New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.



2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 30 June 2022.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is included in the following note:

- Note 11.1 – Assessment of impairment of goodwill

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following note:

- Note 11.1 – Impairment test of goodwill: key assumptions underlying recoverable amounts

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors.

4. Segment and revenue information

For management purposes, the reporting entity is organised into the following major strategic operating segments that offer different products and services:

- 1) GP clinic services;
- 2) Specialist care services;
- 3) Managed healthcare solutions;
- 4) Pharmaceutical services;
- 5) Mobile and digital health services; and
- 6) Others.

These operating segments are reported in a manner consistent with internal reporting provided to Dr. Barry Thng Lip Mong, Chief Executive Officer, who is responsible for allocating resources and assessing performance of the operating segments.



4. Segment and revenue information (cont'd)

4.1 Reportable segments

	6 months ended 30 June 2023							
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Eliminations S\$	Group S\$
Revenue by segment								
External sales	8,185,024	6,642,867	4,874,987	8,025,006	1,344,145	12,607	-	29,084,636
Inter-segment sales	1,233	-	402,685	1,477,653	15,949	2,760,687	(4,658,207)	-
Total revenue	8,186,257	6,642,867	5,277,672	9,502,659	1,360,094	2,773,294	(4,658,207)	29,084,636
EBITDA								
Finance costs	(63,883)	(15,839)	(951)	(9,176)	(118,382)	(66,180)	-	(274,411)
Depreciation and amortisation	(712,854)	(249,382)	(90,526)	(87,798)	(193,768)	(95,425)	-	(1,429,753)
Share of results of an associate	-	-	-	-	(75,660)	-	-	(75,660)
Profit (loss) before tax	925,957	623,870	466,923	1,228,550	(1,735,907)	(1,127,415)	-	381,978
Income tax expense								(333,004)
Profit, net of tax								48,974
Segment assets								
	13,033,937	5,141,194	27,706,748	8,767,659	8,863,615	25,402,293	(23,967,746)	64,947,700
Segment liabilities								
	(5,453,229)	(4,238,572)	(23,420,029)	(4,134,049)	(12,475,512)	(9,983,463)	18,510,144	(41,194,710)
Other material items and reconciliations								
Expenditures for property, plant and equipment	117,654	14,915	231,606	15,414	41,597	926,738	-	1,347,924



4. Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

	6 months ended 30 June 2022							
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Eliminations S\$	Group S\$
Revenue by segment								
External sales	9,684,785	5,994,865	2,850,834	5,237,784	2,411,819	9,134	-	26,189,221
Inter-segment sales	30,979	-	144,620	1,682,285	7,712	3,338,099	(5,203,695)	-
Total revenue	9,715,764	5,994,865	2,995,454	6,920,069	2,419,531	3,347,233	(5,203,695)	26,189,221
EBITDA	3,305,112	959,466	219,792	654,316	(566,703)	(879,899)	-	3,692,084
Finance costs	(39,692)	(10,818)	(717)	(2,942)	(50,118)	(4,041)	-	(108,328)
Depreciation and amortisation	(667,586)	(247,367)	(58,054)	(104,342)	(235,102)	(64,867)	-	(1,377,318)
Share of results of an associate	-	-	-	-	(43,671)	-	-	(43,671)
Profit (loss) before tax	2,597,834	701,281	161,021	547,032	(895,594)	(948,807)	-	2,162,767
Income tax expense								(450,785)
Profit, net of tax								1,711,982
Segment assets	13,166,652	5,187,879	16,599,755	4,997,167	10,315,384	20,694,801	(19,331,704)	51,629,934
Segment liabilities	(5,583,237)	(3,520,733)	(14,352,989)	(1,618,768)	(10,495,192)	(6,114,120)	13,967,210	(27,717,829)
Other material items and reconciliations								
Expenditures for property, plant and equipment	15,824	10,304	40,952	5,926	118,904	90,206	-	282,116



4. Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

	12 months ended 30 June 2023							
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Eliminations S\$	Group S\$
Revenue by segment								
External sales	17,249,734	13,422,033	8,517,390	15,847,142	2,946,425	21,934	-	58,004,658
Inter-segment sales	13,197	-	561,574	2,801,831	25,820	7,608,368	(11,010,790)	-
Total revenue	17,262,931	13,422,033	9,078,964	18,648,973	2,972,245	7,630,302	(11,010,790)	58,004,658
EBITDA	4,013,721	1,885,896	935,543	2,486,481	(2,220,741)	(1,637,494)	-	5,463,406
Finance costs	(114,383)	(31,638)	(1,566)	(11,026)	(194,252)	(67,743)	-	(420,608)
Depreciation and amortisation	(1,380,786)	(502,881)	(147,176)	(164,393)	(426,636)	(183,710)	-	(2,805,582)
Share of results of an associate	-	-	-	-	(82,208)	-	-	(82,208)
Profit (loss) before tax	2,518,552	1,351,377	786,801	2,311,062	(2,923,837)	(1,888,947)	-	2,155,008
Income tax expense								(145,463)
Profit, net of tax								2,009,545
Segment assets	13,033,937	5,141,194	27,706,748	8,767,659	8,863,615	25,402,293	(23,967,746)	64,947,700
Segment liabilities	(5,453,229)	(4,238,572)	(23,420,029)	(4,134,049)	(12,475,512)	(9,983,463)	18,510,144	(41,194,710)
Other material items and reconciliations								
Expenditures for property, plant and equipment	137,775	33,137	318,895	16,699	149,222	1,111,049	-	1,766,777



4. Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

	12 months ended 30 June 2022							
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Eliminations S\$	Group S\$
Revenue by segment								
External sales	18,113,172	10,762,069	5,493,224	11,585,377	8,790,231	12,678	-	54,756,751
Inter-segment sales	47,000	-	292,908	2,243,850	28,382	5,048,928	(7,661,068)	-
Total revenue	18,160,172	10,762,069	5,786,132	13,829,227	8,818,613	5,061,606	(7,661,068)	54,756,751
EBITDA	5,356,619	1,846,970	111,350	1,169,406	943,911	(1,386,938)	-	8,041,318
Finance costs	(87,324)	(20,883)	(1,141)	(7,124)	(90,373)	(20,876)	-	(227,721)
Depreciation and amortisation	(1,354,654)	(493,477)	(116,489)	(202,909)	(421,033)	(207,654)	-	(2,796,216)
Share of results of an associate	-	-	-	-	(66,495)	-	-	(66,495)
Profit (loss) before tax	3,914,641	1,332,610	(6,280)	959,373	366,010	(1,615,468)	-	4,950,886
Income tax expense								(643,374)
Profit, net of tax								4,307,512
Segment assets	13,166,652	5,187,879	16,599,755	4,997,167	10,315,384	20,694,801	(19,331,704)	51,629,934
Segment liabilities	(5,583,237)	(3,520,733)	(14,352,989)	(1,618,768)	(10,495,192)	(6,114,120)	13,967,210	(27,717,829)
Other material items and reconciliations								
Expenditures for property, plant and equipment	26,039	31,071	65,065	15,083	199,901	105,951	-	443,110



4. Segment and revenue information (cont'd)

4.2 Disaggregation of revenue

	Group						
	6 months ended 30 June 2023						
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Group S\$
Types of goods or services							
Rendering of services							
– Medical services	8,185,024	6,642,867	-	-	-	-	14,827,891
– Managed healthcare solutions services	-	-	4,874,987	-	-	-	4,874,987
– Mobile and digital health services	-	-	-	-	1,344,145	-	1,344,145
Sales of goods	-	-	-	8,025,006	-	-	8,025,006
Others	-	-	-	-	-	12,607	12,607
Total revenue	8,185,024	6,642,867	4,874,987	8,025,006	1,344,145	12,607	29,084,636
Timing of revenue recognition:							
At a point in time	8,185,024	6,642,867	4,874,987	8,025,006	1,344,145	12,607	29,084,636
Total revenue	8,185,024	6,642,867	4,874,987	8,025,006	1,344,145	12,607	29,084,636
Geographical information:							
Singapore	8,185,024	6,642,867	4,872,486	6,231,347	1,344,145	12,607	27,288,477
Others ⁽¹⁾	-	-	2,501	1,793,659	-	-	1,796,159
Total revenue	8,185,024	6,642,867	4,874,987	8,025,006	1,344,145	12,607	29,084,636

(1) "Others" include countries from Europe and Asia Pacific Region.



4. Segment and revenue information (cont'd)

4.2 Disaggregation of revenue

	Group						
	6 months ended 30 June 2022						
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Group S\$
Types of goods or services							
Rendering of services							
– Medical services	9,684,785	5,994,865	-	-	-	-	15,679,650
– Managed healthcare solutions services	-	-	2,850,834	-	-	-	2,850,834
– Mobile and digital health services	-	-	-	-	2,411,819	-	2,411,819
Sales of goods	-	-	-	5,237,784	-	-	5,237,784
Others	-	-	-	-	-	9,134	9,134
Total revenue	9,684,785	5,994,865	2,850,834	5,237,784	2,411,819	9,134	26,189,221
Timing of revenue recognition:							
At a point in time	9,684,785	5,994,865	2,850,834	5,237,784	2,411,819	9,134	26,189,221
Total revenue	9,684,785	5,994,865	2,850,834	5,237,784	2,411,819	9,134	26,189,221
Geographical information:							
Singapore	9,684,785	5,994,865	2,847,426	3,766,263	2,411,819	9,134	24,714,292
Others ⁽¹⁾	-	-	3,408	1,471,521	-	-	1,474,929
Total revenue	9,684,785	5,994,865	2,850,834	5,237,784	2,411,819	9,134	26,189,221

(1) "Others" include countries from Europe and Asia Pacific Region.



4. Segment and revenue information (cont'd)

4.2 Disaggregation of revenue (cont'd)

	Group						
	12 months ended 30 June 2023						
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Group S\$
Types of goods or services							
Rendering of services							
– Medical services	17,249,734	13,422,033	-	-	-	-	30,671,767
– Managed healthcare solutions services	-	-	8,517,390	-	-	-	8,517,390
– Mobile and digital health services	-	-	-	-	2,946,425	-	2,946,425
Sales of goods	-	-	-	15,847,142	-	-	15,847,142
Others	-	-	-	-	-	21,934	21,934
Total revenue	17,249,734	13,422,033	8,517,390	15,847,142	2,946,425	21,934	58,004,658
Timing of revenue recognition:							
At a point in time	17,249,734	13,422,033	8,517,390	15,847,142	2,946,425	21,934	58,004,658
Total revenue	17,249,734	13,422,033	8,517,390	15,847,142	2,946,425	21,934	58,004,658
Geographical information:							
Singapore	17,249,734	13,422,033	8,511,787	12,134,525	2,946,425	21,934	54,286,439
Others ⁽¹⁾	-	-	5,603	3,712,617	-	-	3,718,219
Total revenue	17,249,734	13,422,033	8,517,390	15,847,142	2,946,425	21,934	58,004,658

(1) "Others" include countries from Europe and Asia Pacific Region.



4. Segment and revenue information (cont'd)

4.2 Disaggregation of revenue (cont'd)

	Group 12 months ended 30 June 2022						
	GP clinic services S\$	Specialist care services S\$	Managed healthcare solutions S\$	Pharmaceutical services S\$	Mobile and digital health services S\$	Others S\$	Group S\$
Types of goods or services							
Rendering of services							
– Medical services	18,113,172	10,762,069	-	-	-	-	28,875,241
– Managed healthcare solutions services	-	-	5,493,224	-	-	-	5,493,224
– Mobile and digital health services	-	-	-	-	8,790,231	-	8,790,231
Sales of goods	-	-	-	11,585,377	-	-	11,585,377
Others	-	-	-	-	-	12,678	12,678
Total revenue	18,113,172	10,762,069	5,493,224	11,585,377	8,790,231	12,678	54,756,751
Timing of revenue recognition:							
At a point in time	18,113,172	10,762,069	5,493,224	11,585,377	8,790,231	12,678	54,756,751
Total revenue	18,113,172	10,762,069	5,493,224	11,585,377	8,790,231	12,678	54,756,751
Geographical information:							
Singapore	18,113,172	10,762,069	5,486,246	8,890,364	8,790,231	12,678	52,054,760
Others ⁽¹⁾	-	-	6,978	2,695,013	-	-	2,701,991
Total revenue	18,113,172	10,762,069	5,493,224	11,585,377	8,790,231	12,678	54,756,751

(1) "Others" include countries from Europe and Asia Pacific Region.



4. Segment and revenue information (cont'd)

4.2 Disaggregation of revenue (cont'd)

A breakdown of sales:

	Group		
	Financial year ended		Increase / (decrease)
	30 June		
	2023	2022	%
S\$	S\$		
Sales reported for first half year	28,920,022	28,567,530	1.2
Operating profit after tax before deducting minority interests	1,960,571	2,595,530	(24.5)
Sales reported for second half year	29,084,636	26,189,221	11.1
Operating profit after tax before deducting minority interests	48,974	1,711,982	(97.1)

5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group and the Company as at 30 June 2023 and 30 June 2022:

	Group		Company	
	30-Jun-23	30-Jun-22	30-Jun-23	30-Jun-22
	S\$	S\$	S\$	S\$
Financial Assets:				
Financial assets at amortised cost	42,428,460	32,932,178	17,228,935	12,329,747
Financial assets at fair value through profit or loss (FVTPL)	88,475	89,962	-	-
Total	42,516,935	33,022,140	17,228,935	12,329,747
Financial Liabilities:				
Financial liabilities at amortised cost	40,106,764	26,391,768	10,096,812	6,114,118
Financial liabilities at fair value through profit or loss (FVTPL)	-	157,932	-	-
Total	40,106,764	26,549,700	10,096,812	6,114,118



6. Profit before taxation

6.1 Significant items

	Group			
	6 months ended		12 months ended	
	30 June		30 June	
	2023	2022	2023	2022
	S\$	S\$	S\$	S\$
Income				
Other income ⁽¹⁾	(3,962)	(406,244)	(17,361)	(788,774)
Government grants ⁽²⁾	(528,482)	(464,493)	(1,001,436)	(829,645)
Interest income	(5,808)	-	(5,808)	-
Foreign exchange gains	(9,363)	(56,446)	(71,345)	(102,028)
Fair value gain on derivative financial instruments	(53,956)	(40,947)	(53,956)	(40,947)
Expenses				
Interest expense	210,710	62,566	307,561	125,981
Lease interest expense	63,701	45,762	113,047	101,740
Amortisation of intangible assets	59,024	70,960	129,984	141,920
Depreciation of property, plant and equipment	389,269	410,896	790,601	810,949
Depreciation of right-of-use assets	981,460	895,462	1,884,997	1,843,347
Bad debts written off trade receivables	4,166	22,547	4,366	22,864
Allowance (Reversal) for impairment on trade receivables	(694)	(9)	1,779	5,498
Loss on disposal of plant and equipment	271	-	521	-
Plant and equipment written off	-	459	-	459
Fair value loss on derivative financial instruments	190	6,788	190	6,788
Performance share plan expense ⁽³⁾	80,214	-	80,214	-

Notes:

- (1) Other income in FY2022 mainly related to rental rebates received from the various landlords and the reversal of the provision for estimated legal fees and possible penalties after the Court granted a discharge amounting to acquittal for all charges faced by the Relevant Clinics.
- (2) Government grants in FY2023 mainly relate to Digital Leaders Program, Jobs Growth Incentive and various Employment Credits and in respect of FY2022, Jobs Growth Incentive, Rental Support Scheme and various Employment Credits.
- (3) Performance share plan expense related to the value of employee services recognised for Group's performance shares awarded on 3 January 2023 to certain employees of the Group pursuant to the Alliance Healthcare Group Performance Share Plan 2022.



6.2 Related party transactions

There are transactions and arrangements between the Group and related parties and the effects of these on the basis determined between the parties are reflected in these financial statements.

	Group			
	6 months ended 30 June		12 months ended 30 June	
	2023 S\$	2022 S\$	2023 S\$	2022 S\$
<u>An associate:</u>				
Administrative fees income	(9,000)	(10,500)	(18,000)	(14,177)
Interest income	(14,197)	(5,738)	(26,227)	(6,825)
Marketing fee income	(14,500)	(2,000)	(20,500)	(2,000)
Software subscription and system maintenance fee	97,242	41,896	122,679	54,900
Web based software development cost	26,350	51,380	57,375	75,780
<u>Related parties:</u>				
Professional fees expenses	2,417,173	1,795,730	4,709,525	3,356,765
Payments in respect of a lease for premises	26,714	25,350	52,748	50,700

7. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	Group			
	6 months ended 30 June		12 months ended 30 June	
	2023 S\$	2022 S\$	2023 S\$	2022 S\$
<u>Current tax expenses:</u>				
Current tax expenses	448,765	648,446	886,588	715,765
Over adjustments to current tax in respect of prior period	(105,727)	(185,598)	(719,028)	(48,265)
Subtotal	343,038	462,848	167,560	667,500
<u>Deferred tax expense:</u>				
Deferred tax expense	(10,034)	(12,063)	(22,097)	(24,126)
Subtotal	(10,034)	(12,063)	(22,097)	(24,126)
Total income tax expense	333,004	450,785	145,463	643,374



8. Dividends

	Company	
	2023 S\$	2022 S\$
Ordinary dividends paid:		
First & final one-tier tax-exempt dividend paid	925,868	478,143
Dividend per share (net of tax)	0.0045	0.0023

9. Earnings per share

	Group			
	6 months ended		12 months ended	
	2023	2022	2023	2022
Earnings attributable to equity holders of the Company	170,497	1,429,174	2,090,833	3,112,254
Weighted average number of Shares used in computation of basic earnings per share ("EPS")	204,857,744	207,373,601	205,810,818	207,633,092
Basic EPS attributable to equity holders of the Company (cents) ⁽¹⁾	0.08	0.69	1.02	1.50
Fully diluted EPS attributable to equity holders of the Company (cents) ⁽²⁾	0.08	0.69	1.02	1.50

Notes:

- (1) Basic EPS is computed by dividing the Group's earnings attributable to the equity holders of the Company in each financial period by the weighted average number of Shares outstanding during the respective financial period.
- (2) Fully diluted EPS are the same as the basic EPS for the financial periods presented in the table above as the Company did not have any outstanding instruments convertible into rights to subscribe for, and options in respect of its Shares during these financial periods.

10. Net asset value per share

	Group		Company	
	30-Jun-23	30-Jun-22	30-Jun-23	30-Jun-22
Net asset value ("NAV") per ordinary share (cents)	11.09	10.75	8.78	7.82
Number of Shares used in computation of NAV	205,748,352	206,748,352	205,748,352	206,748,352

Net asset value (for the Company and the Group) per ordinary share are computed based on the total number of issued shares (excluding treasury shares, if any) as at the end of the relevant financial period.



11. Intangible assets

	Group			Total S\$
	Goodwill S\$	Customer relationship S\$	Unpatented technology S\$	
At 31 December 2022				
Cost	5,190,858	131,027	810,000	6,131,885
Accumulated amortisation and impairment	-	(129,860)	(347,145)	(477,005)
Net book amount	5,190,858	1,167	462,855	5,654,880
6 months ended 30 June 2023				
Opening net book amount	5,190,858	1,167	462,855	5,654,880
Amortisation charge	-	(1,167)	(57,857)	(59,024)
Closing net book amount	5,190,858	-	404,998	5,595,856
At 30 June 2023				
Cost	5,190,858	131,027	810,000	6,131,885
Accumulated amortisation and impairment	-	(131,027)	(405,002)	(536,029)
Net book amount	5,190,858	-	404,998	5,595,856

11.1 Goodwill impairment

Goodwill is allocated to cash-generating units for the purpose of impairment testing. Each of those cash-generating units (“CGU”) represents the Group’s investment in the following subsidiaries:

Name of subsidiary:	Group	
	30 June 2023 S\$	30 June 2022 S\$
“My Family Clinic”		
Alliance Medical Group Pte. Ltd. ^(a)	1,101,541	1,101,541
My Family Clinic (PN) Pte. Ltd.	128,951	128,951
My Family Clinic (Hougang Central) Pte. Ltd.	780,000	780,000
My Family Clinic (Clementi 325) Pte. Ltd.	596,071	596,071
Sub-total	2,606,563	2,606,563
Jaga-Me Pte. Ltd.	2,584,295	2,584,295
Sub-total	2,584,295	2,584,295
Total	5,190,858	5,190,858

(a) Alliance Medical Group Pte. Ltd. is an investment holding company that holds entities that operate under “My Family Clinic”.

11.1 Goodwill impairment (cont'd)

The goodwill for each of the cash generating unit was tested for impairment at the end of the reporting year. No impairment allowance was recognised because the carrying amount of each of the cash-generating units were lower than their estimated recoverable amounts.

The value in use for each cash generating unit was measured by management. The value in use is a recurring fair value measurement (Level 3). The quantitative information about the value in use measurement using significant unobservable inputs for the cash-generating units are consistent with those used for the measurement last performed, where relevant, and are set out as follows:

<u>CGU – Entities operating under “My Family Clinic”</u>			
<u>Valuation technique and Unobservable inputs</u>			
<u>Discounted cash flow method:</u>			
	<u>2023</u>	<u>2022</u>	
1. Estimated discount rates using pre-tax rates that reflect current market assessments at the risks specific to the CGUs.	15.5%	12.5%	
2. Cash flow forecasts derived from the most recent financial budgets and growth rates approved by management.	5 years 4%	5 years 4 – 8%	
3. Terminal growth rates not exceeding the average long-term growth rate for the relevant markets.	2.0%	2.2%	
<u>CGU – Jaga-Me Pte. Ltd.</u>			
<u>Valuation technique and Unobservable inputs</u>			
<u>Discounted cash flow method:</u>			
1. Estimated discount rates using pre-tax rates that reflect current market assessments at the risks specific to the CGUs.	18%	15%	
2. Cash flow forecasts derived from the most recent financial budgets and growth rates approved by management.	5 years 38%–111%	5 years (46%) ¹ –116%	
3. Terminal growth rates not exceeding the average long-term growth rate for the relevant markets.	2.0%	2.2%	

¹ 2023 forecast at negative 46% growth was to anticipate less COVID related services following Singapore’s move towards endemic.

Actual outcomes could vary from these estimates. If the revised estimated gross margin at the end of the reporting year had been 5% less favourable than management’s estimates at the end of the reporting year, the estimated recoverable amount would still be higher than the carrying amount of goodwill. If the revised estimated pre-tax discount rate applied to the discounted cash flows had been 1 percent point less favourable than management’s estimates, the estimated recoverable amount would still be higher than the carrying amount of goodwill.

12. Property, plant and equipment

During the twelve months ended 30 June 2023, the Group acquired assets amounting to S\$1,766,777 (30 June 2022: S\$443,110), placed deposits of S\$539,333 (30 June 2022: S\$ Nil) for fixed assets which was recorded under other non-financial assets, and disposed of assets of net carry value amounting to S\$521 (30 June 2022: S\$459).



13. Investment properties

The Group does not have any investment properties.

In the Company's balance sheet, the leasehold properties located at 25 Bukit Batok Crescent, Singapore 658066, are classified as investment properties as they are mostly leased out to subsidiaries. However, in the Group's consolidated balance sheet, these leasehold properties are classified as property, plant and equipment.

	Company	
	2023	2022
	S\$	S\$
<u>Cost:</u>		
At 1 July	4,693,069	4,693,069
Additions	990,000	-
At 30 June	<u>5,683,069</u>	<u>4,693,069</u>
<u>Accumulated depreciation:</u>		
At 1 July	872,886	762,953
Depreciation for the year	119,447	109,933
At 30 June	<u>992,333</u>	<u>872,886</u>
<u>Carrying value:</u>		
At 30 June	<u>4,690,736</u>	<u>3,820,183</u>

14. Loans and borrowings

	Group			
	As at 30 Jun 2023		As at 30 Jun 2022	
	Secured	Unsecured	Secured	Unsecured
	S\$	S\$	S\$	S\$
Amount repayable in one year or less, or on demand	1,638,544	596,821	872,895	658,800
Amount repayable after one year	7,260,912	-	4,433,303	-
Total	<u>8,899,456</u>	<u>596,821</u>	<u>5,306,198</u>	<u>658,800</u>



14. Loans and borrowings (cont'd)

Details of any collaterals:

Term loans from DBS Bank Ltd. (“DBS Loans”)

The DBS Loans amounting to S\$1.8 million as at 30 June 2023 (S\$2.0 million as at 30 June 2022) are secured by a first legal mortgage over certain of the Group’s leasehold properties.

Term loan 1 from Oversea-Chinese Banking Corporation Limited (“OCBC Loan 1”)

The OCBC Loan 1 amounting to S\$1.1 million as at 30 June 2023 (S\$1.2 million as at 30 June 2022) is secured by a first legal mortgage over the Group’s leasehold property at Blk 325 Clementi Avenue 5, #01–139, Singapore 120325.

Term loan 2 from Oversea-Chinese Banking Corporation Limited (“OCBC Loan 2”)

The OCBC Loan 2 amounting to S\$0.2 million as at 30 June 2023 (S\$ nil as at 30 June 2022) is secured by Company’s corporate guarantee.

Term loan from United Overseas Bank Limited (“UOB Loan 1”)

The UOB Loan 1 amounting to S\$1.0 million as at 30 June 2023 (S\$1.4 million as at 30 June 2022) is secured by a first fixed charge over 55% shares in the share capital of Jaga-Me Pte. Ltd. (“Jaga-Me”) and a deed of subordination of all current and future non-trade loans/advances which are owing from Alliance Healthcare Pte. Ltd. to its shareholders/related parties.

Term loan from United Overseas Bank Limited (“UOB Property Loans”)

The UOB Property Loans amounting to S\$1.1 million as at 30 June 2023 (S\$0.4 million as at 30 June 2022) are secured by a first legal mortgage over certain of the Group’s leasehold properties.

Term loan from United Overseas Bank Limited (“UOB Loan 2”)

The UOB Loan 2 amounting to S\$1.9 million as at 30 June 2023 (S\$ nil as at 30 June 2022) are secured by a first legal mortgage over certain of the Group’s leasehold properties.

Temporary bridging loan

Temporary bridging loan amounting to S\$1.8 million as at 30 June 2023 (S\$0.3 million as at 30 June 2022) is facility under the Enterprise Financing Scheme Temporary Bridging Loan Programme administered by the Enterprise Singapore which the Government provides 90% risk-share on these loans. S\$0.9 million of the temporary bringing loan is covered by Company’s corporate guarantee (S\$ nil as at 30 Jun 2022).

Finance lease

Finance lease amounting to S\$28,700 as at 30 June 2023 (S\$0.1 million as at 30 June 2022) relates to contracts undertaken by the Group for motor vehicles and equipment.



15. Share capital and treasury shares

	Group and Company			
	2023		2022	
(a) Share capital	Number of shares	S\$	Number of shares	S\$
Issued and fully paid ordinary shares				
Beginning & end of year	207,888,352	14,684,250	207,888,352	14,684,250

There was no change in the Company's share capital between 31 December 2022 (being the end of the previous period reported on) and 30 June 2023. The Company did not have any outstanding options or convertible instruments as at 30 June 2023 and 30 June 2022.

The Company did not have any subsidiary holdings as at 30 June 2023 and 30 June 2022.

The Company's subsidiaries do not hold any shares in the Company as at 30 June 2023 and 30 June 2022.

	Group and Company			
	2023		2022	
(b) Treasury shares	Number of shares	S\$	Number of shares	S\$
At 1 July	1,140,000	199,400	-	-
Shares buy-back during the year	1,000,000	173,960	1,140,000	199,400
At 30 June	2,140,000	373,360	1,140,000	199,400

During the financial year, the Company acquired 1,000,000 (2022: 1,140,000) of its ordinary shares by way of on-market purchase for a total consideration of S\$173,960 (2022: S\$199,400). These shares buyback are presented under treasury shares as a component within equity.

	Group and Company	
	2023	2022
Total number of issued shares excluding treasury shares	205,748,352	206,748,352

16. Acquisition or incorporation of subsidiaries without a change in control

Call and Put Options

All capitalised terms used herein shall have the same meaning as ascribed thereto in the announcement by the Company dated 19 December 2019 in relation to the proposed acquisition of 55% shareholding interest in Jaga-Me by the Company's wholly-owned subsidiary, Alliance Healthcare Pte. Ltd. ("AHPL").

Pursuant to the terms of the Amended and Restated SHA, AHPL shall have a Call Option to purchase all (and not only some) of the Jaga-Me Shares held by the Relevant Shareholders. Each Relevant Shareholder shall have a Put Option to sell all (and not only some) of such Relevant Shareholder's respective Jaga-Me Shares to AHPL. The Call Option and Put Option, if exercised by AHPL or all of the Relevant Shareholders, comprise 292,854 of Jaga-Me Shares.

The Put Option is exercisable within 3 months from the date of Jaga-Me's audited accounts for the previous, most recently completed financial year which indicates:

- (i) Jaga-Me's net operating profit after tax ("**NOPAT**") is S\$1.5 million or higher, in which case the Put Option shall be exercisable at S\$4.80 per Jaga-Me Share; or



16. Acquisition or incorporation of subsidiaries without a change in control (cont'd)

- (ii). Jaga-Me's NOPAT is below S\$1.5 million, but its operating revenue is S\$4 million or higher, in which case the Put Option shall be exercisable at S\$3.00 per Jaga-Me Share.

In any event, if the Put Option is not exercised on or before 30 June 2023, the Put Option shall irrevocably expire and shall lapse and shall cease to be exercisable.

The Put Option Consideration shall be satisfied, at the sole discretion of AHPL, by way of (i) cash; and/or (ii) shares in the Company; or (iii) a combination of cash and shares in the Company.

Based on Jaga-Me's audited accounts for the financial year ended 30 June 2022, its NOPAT was below S\$1.5 million but its operating revenue was above S\$4 million. Hence, the Put Option was exercisable at S\$3.00 per Jaga-Me Share.

On 30 December 2022 ("**Date of the Put Option Exercise Notice**"), a non-controlling shareholder of Jaga-Me ("**Exercising Shareholder**") exercised the Put Option. On 9 January 2022 the Exercising Shareholder sold 6,731 Jaga-Me Shares ("**Put Option Shares**") at S\$3.00 per Jaga-Me Share for a cash consideration of S\$20,193 ("**Put Option Consideration**") to AHPL. The net asset value represented by such Put Option Shares as of 30 June 2022 is approximately S\$9,615.

The Put Option Shares represent approximately 0.27% of the issued share capital of Jaga-Me. Accordingly, following this acquisition, the Group's shareholding interest in Jaga-Me increased from 64.6% to 64.9%.

The remaining unexercised Put Option was expired on 30 June 2023.

Acquisition of Jaga-Me Shares from a Jaga-Me Co-Founder

On 9 January 2023 ("**Date of Instrument of Transfer**"), one of the Jaga-Me's co-founders ("**Jaga-Me Co-Founder**") and AHPL executed an instrument of transfer, pursuant to which the Jaga-Me Co-Founder sold 260,139 Jaga-Me Shares ("**Co-Founder's Disposal Shares**") at S\$3.00 per Jaga-Me Share for a cash consideration of S\$780,417 ("**Consideration**") to AHPL. The Consideration was arrived at on a willing-buyer, willing-seller basis, after taking into account, amongst others, Jaga-Me's operating profit for the most recently completed financial year based on Jaga-Me's audited accounts and the exercise price of the Put Option. The net asset value represented by such Co-Founder's Disposal Shares as of 30 June 2022 is approximately S\$371,593.

The Co-Founder's Disposal Shares represent approximately 10.4% of the issued share capital of Jaga-Me. Accordingly, following this acquisition, the Group's shareholding interest in Jaga-Me increased from 64.9% to 75.3%.

17. Acquisition of an associate

There was no change in the Company's investment in an associate between 31 December 2022 (being the end of the previous period reported on) and 30 June 2023.

18. Subsequent events

There are no subsequent events to be disclosed or which would have led to adjustments to this set of unaudited interim financial statements.



F. Other information required by Appendix 7C of the Catalyst Rules

1A. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The condensed consolidated statement of financial position of Alliance Healthcare Group Limited and its subsidiaries as at 30 June 2023 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the twelve-month period then ended and certain explanatory notes have not been audited or reviewed.

1B. Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).

Not applicable.

1C. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:

- (a) Updates on the efforts taken to resolve each outstanding audit issue.
- (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable.

2. Review of performance of the Group

Review of financial performance of the Group for FY2023 compared to FY2022

Revenue

Revenue increased by approximately S\$3.2 million or 5.9% from S\$54.8 million in FY2022 to S\$58.0 million in FY2023.

The overall increase in revenue was mainly attributable to an increase in sales generated by the following business segments: managed healthcare solutions, pharmaceutical services and specialist care services. These were partially offset by a decrease in revenue from the mobile and digital health services business segment and GP clinic services.

The overall increase in the Group's revenue was a result of the following:

(a) Managed Healthcare Solutions

Revenue from managed healthcare solutions business segment increased by approximately S\$3.0 million or 54.5% from S\$5.5 million in FY2022 to S\$8.5 million in FY2023, mainly due to higher patient volume, more corporate clients engaged and an additional in-house corporate clinic established in January 2023.



2. Review of performance of the Group (cont'd)

Review of financial performance of the Group for FY2023 compared to FY2022 (cont'd)

(b) Pharmaceutical Services

Revenue from pharmaceutical services increased by approximately S\$4.2 million or 36.2% from S\$11.6 million in FY2022 to S\$15.8 million in FY2023. Local sales within Singapore and overseas sales increased by S\$3.2 million and S\$1.0 million respectively. The increase was mainly due to an increase in demand for medical supplies from certain hospitals, institutions and overseas clients.

(c) Specialist Care Services

Revenue from specialist care services increased by approximately S\$2.6 million or 24.1% from S\$10.8 million in FY2022 to S\$13.4 million in FY2023, mainly due to more local and overseas patients seeking procedures after the post-pandemic phase.

(d) Mobile and Digital Health Services

Revenue from mobile and digital health services decreased by approximately S\$5.9 million or 67.0% from S\$8.8 million in FY2022 to S\$2.9 million in FY2023. This was mainly due to decrease in demand for COVID-19 related healthcare services in view of further easing of COVID-19 measures in Singapore as well as globally. The decrease was partially offset by increase in demand for telemedicine services during the year.

(e) GP Clinic Services

Revenue from GP clinic services decreased by approximately S\$0.9 million or 5.0% from S\$18.1 million in FY2022 to S\$17.2 million in FY2023, mainly due to less patient visit for pre-departure test ("PDT") after the removal of PDT requirements from 26 April 2022 and the temporary closure of My Family Clinic (TH) Pte. Ltd. ("MFC(TH)") since December 2021 due to Housing Development Board's clearance programme. MFC(TH) has been relocated to Margaret Drive and commenced operation in June 2023.

Interest income

The interest income is related to interest received from fixed deposit and there was no interest income in FY2022.

Other income and gains

Other income and gains, mainly consisting of government grants and incentives, decreased by approximately S\$0.7 million or 35.0% from S\$1.8 million in FY2022 to S\$1.1 million in FY2023, mainly due to the cessation of the rental rebates for most of the clinics from July 2022 onwards. In FY2022, after the Court granted a discharge amounting to acquittal for all charges faced by the Relevant Clinics (as defined in the Company's announcement dated 29 June 2021), the Group reversed the provision of estimated legal fees and possible penalties of S\$0.3 million made in FY2021 relating to the charges concerning a locum doctor.

Consumables and medical supplies used

Consumables and medical supplies used mainly relate to the Group's GP clinic services, specialist care services, pharmaceutical services business segment and mobile and digital health services business segment.



2. Review of performance of the Group (cont'd)

Review of financial performance of the Group for FY2023 compared to FY2022 (cont'd)

Consumables and medical supplies used increased by approximately S\$2.7 million or 16.8% from S\$15.6 million in FY2022 to S\$18.3 million in FY2023, mainly due to an increase of consumables and medical supplies used for the pharmaceutical services business segment and the specialist care service business segment in line with the increase in their revenue. The increase was partially offset by less consumables and medical supplies used for mobile and digital health services and GP clinics in line with the decrease in their revenue.

Employee benefits expense

Employee benefits expense relates to salaries, bonuses, benefits, fees and other payment made to (i) the Group's employees, (ii) doctors (including locum and full-time GP doctors who may not be the Group's employees), (iii) nurses (including locum and full-time nurses who may not be the Group's employees) and (iv) specialists with whom the Group has entered into contracts for provision of medical services. In respect of such doctors (except for locum doctors and nurses who are paid on an hourly basis) and specialists with whom the Group entered into contracts, the amount of fees is generally determined based on a base salary and/or the profitability of the relevant clinic.

Employee benefits expense increased by approximately S\$1.9 million or 6.5% from S\$29.4 million in FY2022 to S\$31.3 million in FY2023. This was mainly due to the net effect of the following:

- (a) an increase of approximately S\$4.5 million mainly due to the increase in salaries and defined contribution plan of employees as a result of an increase in headcount of employees and doctors and increase in business activities in the Managed Healthcare Solutions and Specialist Care Services business segments; and
- (b) a decrease of approximately S\$2.6 million relating to locum doctors and locum nurses in line with the decrease in business activities in the mobile and digital health services business segments;

Depreciation and amortisation expense

Depreciation and amortisation expense amounted to approximately S\$2.8 million in FY2023 which was comparable to the amount reported in FY2022.

Other losses

Other losses were not significant in FY2023 and FY2022.

Finance costs

Finance costs increased by approximately S\$0.2 million or 84.7% from S\$0.2 million in FY2022 to S\$0.4 million in FY2023, due to additional loan drawn down and increased interest rate during the year.

Other expenses

Other expenses increased by approximately S\$0.7 million or 21.0% from S\$3.4 million in FY2022 to S\$4.1 million in FY2023, mainly due to higher marketing expense and distribution costs amid general global inflation in FY2023.



2. Review of performance of the Group (cont'd)

Review of financial performance of the Group for FY2023 compared to FY2022 (cont'd)

Share of results of an associate

The Group's share of losses from an associate in FY2023 was S\$82,000 as compared to the share of losses of S\$66,000 in FY2022.

Profit before tax

As a result of the above, profit before tax decreased by approximately S\$2.8 million or 56.5% from S\$5.0 million in FY2022 to S\$2.2 million in FY2023.

Income tax expense

The Group incurred an income tax expense of approximately S\$0.1 million in FY2023 compared to an income tax expense of approximately S\$0.6 million in FY2022. This was the net effect of lower profit before tax and tax refund received in respect of Group relief and utilisation of trade losses of prior years in FY2023.

Profit attributable to owners of parent, net of tax

As a result of the above, net profit attributable to equity holders of the Company decreased by approximately S\$1.0 million from S\$3.1 million in FY2022 to S\$2.1 million in FY2023.

Financial performance by operating segments

In FY2023, the managed healthcare solutions, GP clinic services, specialist care services, pharmaceutical services and mobile and digital health services business segments contributed 14.7%, 29.8%, 23.1%, 27.3% and 5.1% of the Group's revenue, respectively.

In FY2022, the managed healthcare solutions, GP clinic services, specialist care services, pharmaceutical services and mobile and digital health services business segments contributed 10.0%, 33.0%, 19.7%, 21.2% and 16.1% of the Group's revenue, respectively.

Compared to FY2022, the net profit before tax margins of the pharmaceutical services had improved while the net profit before tax margin of the GP clinic services and specialist care services business segment had decreased. Managed healthcare solutions business segment turned profitable in FY2023 with higher volume of patient visits as Singapore entered the post-pandemic phase and an additional in-house corporate clinic was established since January 2023. However, mobile and digital health services business segment recorded a loss in FY2023 due to the decline in demand for COVID-19 related services in view of further easing of COVID-19 measures in Singapore as well as globally.

The Group's revenue is primarily generated from its operations in Singapore. The revenue generated from overseas mainly relates to its pharmaceutical services business segment. In FY2023, Singapore and overseas markets contributed approximately 93.6% and 6.4% of the Group's revenue respectively. In FY2022, Singapore and overseas markets contributed approximately 95.1% and 4.9% of the Group's revenue respectively.



2. Review of performance of the Group (cont'd)

Review of financial position of the Group as at 30 June 2023

Non-current assets

Non-current assets increased by approximately S\$2.6 million, from S\$16.0 million as at 30 June 2022 to S\$18.6 million as at 30 June 2023 mainly as a net result of the following:

- (a) an increase in the carrying value of property, plant and equipment and right-of-use assets of approximately S\$2.7 million as a result of addition of leasehold properties of \$1.0 million, addition of new plant and equipment of \$0.8 million and additional and renewal of leases of an aggregate value of S\$3.5 million, partially offset by the depreciation and amortisation of S\$2.7 million charged for property, plant and equipment and right-of-use assets;
- (b) a loan of S\$0.2 million to an associate; and
- (c) share of losses from an associate of approximately S\$82,000 for FY2023.

Current assets

Current assets increased by approximately S\$10.7 million, from S\$35.6 million as at 30 June 2022 to S\$46.3 million as at 30 June 2023. This was the net effect of an increase in trade and other receivables of approximately S\$10.4 million, an increase of other non-financial assets of \$0.7 million and an increase of inventory of S\$0.8 million, partially offset by a decrease in cash and cash equivalents of S\$1.1 million.

The increase in trade and other receivables was mainly due to the increased service provision, increased sales of medical supplies and increased medical claims towards end of FY2023 which were pending for verification and reimbursement by insurers and corporate clients as at 30 June 2023.

The increase in other non-financial assets was mainly due to the deposit paid for the new warehouse leased for our pharmaceutical business segment.

The increase of inventory was in line with the increased sales of medical supplies, commencement of an additional corporate clinic in January 2023, reopening of MFC(TH) in June 2023 and opening an additional corporate clinic in July 2023.

Total equity

Shareholders' equity increased by S\$0.6 million from S\$22.2 million as at 30 June 2022 to S\$22.8 million as at 30 June 2023 mainly as a net result of the following:

- (a) an increase in retained earnings of S\$1.1 million (net profit attributable to equity holders of the Company of S\$2.0 million, offset by the payment of dividends of S\$0.9 million);
- (b) value of employee services amounting to S\$80,200 was recognised for Group's performance shares awarded on 3 January 2023 to certain employees of the Group pursuant to the Alliance Healthcare Group Performance Share Plan 2022;
- (c) acquisition of 1,000,000 of the Company's ordinary shares by way of on-market purchase for a total consideration of S\$173,960; and
- (d) acquisition of additional shares from certain non-controlling shareholder of which a capital reserve of S\$0.5 million was recorded.



2. Review of performance of the Group (cont'd)

Review of financial position of the Group as at 30 June 2023

Non-controlling interests decreased by S\$0.9 million to S\$0.9 million as a result of payment of dividends of S\$0.4 million to non-controlling interests, increase in Group's shareholding interest in Jaga-Me of S\$0.3 million and net loss attributable to non-controlling interests of the Company of S\$0.1 million.

Non-current liabilities

Non-current liabilities increased by S\$4.0 million from S\$5.7 million as at 30 June 2022 to S\$9.7 million as at 30 June 2023 mainly due to additional non-current loans and borrowings of S\$2.9 million for business operation and acquisition of leasehold properties, and additional non-current lease liabilities of S\$1.2 million in line with additional and renewal of leases during the year.

Current liabilities

Current liabilities increased by S\$9.4 million, from S\$22.1 million as at 30 June 2022 to S\$31.5 million as at 30 June 2023, mainly due to an increase in trade and other payables of S\$8.3 million largely attributable to the business segment of managed healthcare solutions and pharmaceutical services in line with increase of medical claims and higher medical supplies purchased towards end of the FY2023, additional loans and borrowings of S\$0.7 million after netting loan repayments and increased lease liabilities of S\$0.4 million in line with additional and renewal of leases during the year, partially offset by a decrease in other non-financial liabilities following the expiring of the put option on 30 June 2023.

Review of statement of cash flow for FY2023

The Group generated net cash of S\$2.5 million from operating activities in FY2023, mainly due to operating cash flows before changes in the working capital of S\$5.5 million, partially offset by net working capital outflows of S\$2.8 million and income taxes paid of S\$0.2 million.

The net working capital outflows was a result of an increase in trade and other receivables by S\$10.5 million and an increase in inventories by S\$0.8 million, partially offset by an increase in trade and other payables by S\$8.6 million.

Net cash flows used in investing activities during FY2023 amounted to S\$3.3 million were mainly due to the purchase of property, plant and equipment of S\$2.3 million, the acquisition of Jaga-Me shares from a Jaga-Me Co-Founder and Put Option Shares for a cash consideration of S\$0.8 million and S\$20,200 respectively and the disbursement of a loan amounted S\$0.2 million to an associate.

Net cash flows used in financing activities amounted to S\$0.3 million during FY2023, mainly due to the payment of lease liabilities of S\$2.0 million, the repayment of bank borrowings and interest of S\$1.1 million and S\$0.3 million respectively, the payment of dividends of S\$0.9 million and S\$0.4 million to equity holders of the Company and non-controlling shareholders respectively and share buyback of S\$0.2 million, repayment of non-controlling shareholders' loan of S\$0.1 million, partially offset by the new loan of S\$4.7 million.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

There has not been any forecast or prospect statement in relation to the Group's results for the twelve months ended 30 June 2023 previously disclosed to shareholders.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next operating period and the next 12 months

With Singapore in the post-pandemic phase, the demand for COVID-19-related medical services has reduced substantially. The tapering off of the COVID-19-related revenue and the inflation-led increase in drug and staffing costs will continue to exert downward pressure on the Group's bottom line.

However, the Group sees opportunities for business growth as Singapore tackle the challenges of a rapidly-ageing population and rising healthcare costs.

The Healthier SG initiative was launched on 5 July 2023 for Singapore Citizens and Permanent Residents, starting with those aged 60 years and above. This programme will be progressively rolled out to other Singapore Citizens and Permanent Residents and is expected to benefit over two million Singapore residents aged 40 and above by end-2024. Healthier SG focuses on promoting health prevention and for every Singaporean to have a trusted and lifelong relationship with their family doctors. The Group believes this initiative will allow primary care physicians to provide continuing care for their patients across the entire health continuum and will increase demand for our GP services.

GP clinics participating in the Healthier SG programme are strongly encouraged to use a clinic management system ("CMS") that is Healthier SG-enabled. These systems are designed with functional features to facilitate the running of Healthier SG and provide secured access to the National Electronic Health Record ("NEHR"). The Group's associate company, SGiMed Pte Ltd, is amongst an early group of private clinic management solution vendors that attained a tier-1, Healthier SG-enabled status by Synapse, the national HealthTech Agency. As a result, the Group saw a significant increase in the demand for SGiMed's Hummingbird SmartCMS and, barring any unforeseen circumstances, the subscriptions of Hummingbird SmartCMS should continue to increase in tandem with the rolling out of the Healthier SG programme.

The Mobile Inpatient Care at Home ("MIC@Home") pilot, launched in April 2022, allows patients to be cared for in their homes instead of in a hospital ward. Following its implementation at hospitals under the National University Health System, Singapore General Hospital and Khoo Teck Puat Hospital, MIC@Home has been expanded to four more hospitals: Changi General Hospital, KK Women's and Children's Hospital, Sengkang General Hospital and Tan Tock Seng Hospital. In July 2023, MOH announced that the MIC model would be expanded to approximately 100 to 200 MIC@Home beds with more medical conditions covered under the programme. As a result, government-restructured hospitals are increasing their collaborations with private home care service providers to support their MIC@Home patients in the community.

MOH has recently made the following announcements:

- From 1 October 2023, MOH will allow subvented home medical and nursing providers to submit MediSave claims for homebound patients to enhance access to home care services. When the scheme stabilises, MOH will extend this arrangement to other non-subvented home medical and nursing providers.



4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next operating period and the next 12 months (cont'd)

- In 2024, MOH will enhance subsidies for palliative care, adjust the MediShield Life claim limits for inpatient palliative care, and remove the MediSave lifetime withdrawal limit for home palliative care and day hospice patients who use their own MediSave. This arrangement could improve affordability and access to palliative care.

With these developments and policy changes, the Group believes the pace of decentralisation of healthcare services will quicken as a tool to help contain healthcare costs and provide an alternative care option for patients. The MIC@Home pilot will continue to gain momentum and could eventually become a mainstream service public and private hospitals offer. MOH may also further calibrate its healthcare financing policies to improve accessibility and affordability of home care services. Alliance is working towards seizing the opportunities that may arise from these developments.

5. Dividend Information

5(a) Current Financial Period Reported On

Any dividend recommended for the current financial period reported on?

Yes. The first and final dividend in respect of FY2023 (“**Final Dividend**”), as proposed below, is subject to the approval of shareholders at the Company’s annual general meeting to be held on 30 October 2023.

Name of dividend	First and Final
Dividend type	Cash
Dividend amount per share (in cents)	0.30 cents per ordinary share
Tax rate	Tax exempt (one-tier)

5(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year?

Yes.

Name of dividend	First and Final
Dividend type	Cash
Dividend amount per share (in cents)	0.45 cents per ordinary share
Tax rate	Tax exempt (one-tier)

5(c) Date Payable

The Final Dividend, if approved by the shareholders of the Company at the forthcoming annual general meeting of the Company, will be paid on 15 November 2023.

5(d) Books Closure Date

Subject to the approval of the shareholders being obtained for the Final Dividend at the forthcoming annual general meeting of the Company to be held on 30 October 2023 (Monday), the Register of Members and the Transfer of Books of the Company will be closed from **3 November 2023 (Friday)** at 5.00 p.m. for the preparation of dividend warrants.



5. Dividend Information (cont'd)

5(d) Books Closure Date

Duly completed registrable transfers received by the Company's Share Registrar, Tricor Barbinder Share Registration Services, at 80 Robinson Road, #02-00, Singapore 068898 before 5.00 p.m. on **3 November 2023 (Friday)**, will be registered to determine shareholders' entitlement to the Final Dividend.

6. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision.

Not applicable.

7. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year as follows:

	FY2023 S\$	FY2022 S\$
Total annual ordinary dividend		
Interim (Tax exempt one-tier)	-	-
Final (Tax exempt one-tier)	617,245	925,868
Total	617,245	925,868

The proposed Final Dividend represents 30% (FY2022: 30%) of the Group's profits attributable to owners of the parent.

8. If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company did not obtain any general mandate from its shareholders in respect of any interested person transaction. The Company did not have any interested person transaction equal to or exceeding S\$100,000 during FY2023.

9. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)

The Company confirms that it has already procured signed undertakings from all of its Directors and relevant executive officers in the format as set out in Appendix 7H of the Catalist Rules in accordance with Rule 720(1) of the Catalist Rules.

10. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

Pursuant to Rule 704(10) of the Catalist Rules, the Company confirms that, none of the persons occupying managerial positions in the Company or any of its principal subsidiaries is a relative of a director or the chief executive officer or substantial shareholder of the Company.



11. Utilisation of proceeds from the Company's initial public offering ("IPO")

As at the date of this announcement, the status on the use of the IPO proceeds is as follows:

	Allocated S\$'000	Utilised S\$'000	Balance S\$'000
(i) To expand business through (a) the expansion of network of self-owned GP clinics, specialist care services and medical facilities in Singapore as well as (b) acquisitions, joint ventures and/or strategic alliances	3,000	3,000	-
(ii) To invest in technology systems as part of the digital transformation of the delivery of healthcare services	500	500	-
(iii) To expand pharmaceutical services business	200	200	-
(iv) For general working capital requirements ⁽¹⁾⁽²⁾	1,028	1,028	-
(v) For payment of underwriting and placement commissions as well as listing expenses ⁽¹⁾	1,672	1,672	-
(vi) Gross proceeds from IPO	6,400	6,400	-

Notes:

- (1) The Company incurred actual IPO expenses of S\$1.672 million. The amount of S\$189,000 in excess of the estimated IPO expenses of S\$1.861 million has been re-allocated for general working capital purposes.
- (2) The Company has fully utilised the amount allocated for general working capital requirements for purchase of inventories.

The above utilisation is in accordance with the intended use of proceeds from the IPO as stated in the offer document dated 24 May 2019.

12. Acquisition or sale of shares in subsidiaries and/or associated companies under Rule 706(A)

My Family Clinic (Punggol Waterway Terrace) Pte. Ltd. ("**PWT**"), an indirect 80%-owned subsidiary of the Company which has ceased business since 14 July 2018, has submitted an application to the Accounting and Corporate Regulatory Authority ("**ACRA**") on 17 April 2023 to strike its name off from the Register of Companies pursuant to Section 344A of the Companies Act, Chapter 50 of Singapore (the "**Strike-Off**"). PWT has been struck off from the Register on 7 August 2023. PWT was principally engaged in the provision of medical services. The Strike-Off was due to PWT being a dormant company.

Save as disclosed above and in notes 16 and 17 to the condensed interim financial statements, there is no other acquisition and/or sale of shares in any subsidiaries or associated companies of the Group since 31 December 2022 (being the end of the previous period reported on) and up to the date hereof which is required to be reported under Rule 706(A) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst ("**Catalist Rules**").

BY ORDER OF THE BOARD

BARRY THNG LIP MONG
Executive Chairman and CEO

28 August 2023